Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …

BCL2 and MCL1 are commonly expressed prosurvival (antiapoptotic) proteins in
hematologic cancers and play important roles in their biology either through dysregulation or …

RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged≥ 65 years …

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this
first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3+ 3 dose …

Background We hypothesised that zanubrutinib, a highly selective next-generation Bruton
tyrosine kinase (BTK) inhibitor, would be a safe and active treatment for patients intolerant of …

Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis
of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of …

The cytoplasmic protein-tyrosine kinase BTK plays an essential role for differentiation and
survival of B-lineage cells and, hence, represents a suitable drug target. The number of BTK …

Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown
superior efficacy to chlorambucil monotherapy and are standard first-line treatments in …

Background New treatments have improved outcomes for patients with relapsed chronic
lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a …

Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ
and γ (PI3K-δ, γ) being developed for treatment of hematologic malignancies. PI3K-δ, γ …